Meeting
2013 ASCO Annual Meeting
A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC).
Authors
Jochen H. Lorch
Dana-Farber Cancer Institute, Boston, MA
Jochen H. Lorch , Naifa Busaidy , Daniel T Ruan , Pasi A. Janne , Sewanti Atul Limaye , Lori J. Wirth , Justine A. Barletta , Guilherme Rabinowits , Levi A. Garraway , Eliezer Mendel Van Allen , Nikhil Wagle , Glenn J. Hanna , Krzysztof Misiukiewicz , Margaret Suda , Tyler C Haddad , Catherine E Devine , Amy Williams , Ghulam Warsi , Marshall R. Posner , Robert I. Haddad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT00936858
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6023)
DOI
10.1200/jco.2013.31.15_suppl.6023
Abstract #
6023
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).
First Author: Jochen H. Lorch
Poster
2015 ASCO Annual Meeting
Combination of everolimus and sorafenib in the treatment of thyroid cancer: Update on phase II study.
First Author: Eric Jeffrey Sherman
Poster
2017 ASCO Annual Meeting
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
First Author: Jiaying Chen
Poster
2017 ASCO Annual Meeting
Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).
First Author: Bernard Tawfik